All In Biotech

Drug Trial Radar · NCT06672237

A Phase 3 Study of NTLA-2001 in ATTRv-PN

MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

67

Actual

Start

Nov 22, 2024

Primary completion

Jul 2027

Study completion Aug 2028

Sponsor

Lead sponsor
Intellia TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.

Conditions

  • Neuromuscular Disease
  • Neuromuscular Diseases (NMD)
  • Neurodegenerative Disease
  • Neurodegenerative Disease, Hereditary
  • Neurodegenerative Diseases
  • Neuromuscular Diseases
  • Nerve Disorders
  • Nervous System Disease
  • Nervous System Diseases
  • Genetic Disease, Inborn
  • Amyloidosis, Familial
  • Amyloidosis, Hereditary
  • Amyloidosis
  • Polyneuropathies
  • Amyloid Neuropathies
  • Amyloid Neuropathies, Familial
  • Peripheral Nervous System Disease
  • Peripheral Nervous System Diseases
  • Metabolism, Inborn Errors
  • Metabolic Diseases

Interventions

  • nexiguran ziclumeranBiological

    nexiguran ziclumeran 55 mg by single IV infusion

  • Normal Saline as PlaceboDrug

    Normal saline (0.9% NaCl) by single IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Neuropathy Impairment Score +7 (mNIS+7)Time frame: 18 Months
  2. Serum TTRTime frame: 29 Days

Locations

14 sites in 6 countries. Site status is shown where the registry gives one.

  • Hospital Británico de Buenos Aires

    Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires (HIBA)

    Buenos Aires, Argentina

  • Hospital El Cruce

    San Juan Bautista, Argentina

  • Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)

    Campinas, Brazil

  • HCFMRP - Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto

    Ribeirão Preto, Brazil

  • Instituto de Educacao, Pesquisa e Gestao em Saude

    Rio de Janeiro, Brazil

  • PSEG Centro de Pesquisa Clinica S.A.

    São Paulo, Brazil

  • National Institute of Medical Sciences and Nutrition - Salvador Zubiran (INCMNSZ)

    Tlalpan, Mexico

  • National University Hospital

    Singapore, Singapore

  • Singapore General Hospital

    Singapore, Singapore

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Chang Gung Medical Foundation - Linkou Branch

    Taoyuan, Taiwan

  • Siriraj Hospital

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.